Gregory S. Curhan - Mar 2, 2022 Form 4 Insider Report for Angion Biomedica Corp. (ELTX)

Role
Chief Financial Officer
Signature
/s/ Jennifer J. Rhodes, as attorney-in fact for Gregory S. Curhan
Stock symbol
ELTX
Transactions as of
Mar 2, 2022
Transactions value $
$0
Form type
4
Date filed
3/4/2022, 03:20 PM
Previous filing
Dec 16, 2021
Next filing
Aug 20, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELTX Stock Option (Right to Buy) Award $0 +100K $0.00 100K Mar 2, 2022 Common Stock 100K $1.99 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The total number of options vest in forty-eight (48) successive and equal monthly installments as measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the options will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Chief Financial Officer